Ceramidase

Ceramidases are a group of enzymes that catalyze the hydrolysis of ceramide, dihydroceramide, and phytoceramide into sphingosine (SPH), dihydrosphingosine (DHS), and phytosphingosine (PHS), respectively, along with a free fatty acid. Ceramide catabolism is controlled by ceramidases that are pivotal in the pathophysiology of these diseases of altered lipid homeostasis such as Alzheimer’s disease, type 2 diabetes-induced insulin resistance, cancer, and cardiovascular diseases. Ceramidases are classified into the acid, neutral, and alkaline ceramidase subtypes according to the pH optima for their catalytic activity.

Ceramidase Related Products (12):

By Effects:	Inhibitors (8) Agonist (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-B0182

Carmofur	Inhibitor	99.95%
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).

HY-141866

Acid Ceramidase-IN-1		99.36%
Acid Ceramidase-IN-1 is a potent and oral bioavailable acid ceramidase (AC, ASAH-1) inhibitor (hAC IC₅₀=0.166 μM). Acid Ceramidase-IN-1 has excellent brain penetration in mice.

HY-103592

ARN14974	Inhibitor	99.29%
ARN14974, a benzoxazolone carboxamide, is a potent and systemically active inhibitors of intracellular acid ceramidase (IC₅₀=79 nM).

HY-103359

Ceranib1		99.38%
Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells.

HY-153396

Acid Ceramidase-IN-2	Inhibitor	≥99.0%
Acid Ceramidase-IN-2 (compound 1) is an acid ceramidase inhibitor with potentially antiproliferative and cytostatic activities. Moreover, human acid ceramidase is overexpressed in prostate cancer cells, indicating potential anti-tumor effect of Acid Ceramidase-IN-2. And Acid Ceramidase-IN-2 hydrolysis can be inhibited by 3 a-ketoamides GT85, GT98 and GT99 inhibits in vitro.

HY-139062

C6 Urea Ceramide	Inhibitor
C6 Urea Ceramide (Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. C6 Urea Ceramide increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells. C6 Urea Ceramide (5-10 μM) inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but is not toxic to non-cancerous cells. C6 Urea Ceramide decreases total and phosphorylated β-catenin levels in HT-29 and HCT116 cells, and induces colocalization of β-catenin with the 20S proteasome. C6 Urea Ceramide (1.25, 2.5, and 5 mg/kg) reduced tumor growth and increased C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.

HY-124134

AD-2646	Inhibitor
AD-2646 (LCL102), a ceramide analog, can kill leukemic T cells (EC₅₀: 40 μM). AD-2646 triggers the cleavage of caspase-8, -9 and -3, as well as the caspase substrate PARP. AD-2646 is a ceramidase inhibitor. AD-2646 induces an accumulation of endogenous ceramide owing to perturbed ceramide metabolism.

HY-137422

D-erythro-MAPP		≥98.0%
D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC₅₀ of 1-5 μM in vitro.

HY-121975

N-Cyclohexanecarbonylpentadecylamine	Inhibitor
N-Cyclohexanecarbonylpentadecylamine (Compound 1) is an inhibitor of N-Acylethanolamine hydrolyzing acid amidase (NAAA) with an IC₅₀ of 4.5 μM. N-Cyclohexanecarbonylpentadecylamine can be used in the research of inflammation and pain.

HY-158783

SACLAC	Inhibitor
SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a K_i of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models.

HY-163106

W000113414_I13	Agonist
W000113414_I13 is an acid ceramidase (AC) inhibitor. W000113414_I13 exhibits dose-dependent inhibition of AC with an IC₅₀ value of 6.6?μM. W000113414_I13 can be used for the research of cancer.

HY-B0182R

Carmofur (Standard)	Inhibitor
Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).

Name
Email *

	Sorry, but the email address you supplied was invalid.